# Anidulafungin in Patients With Hematologic Malignancies

> **NCT01053884** · PHASE2 · TERMINATED · sponsor: **Elisabethinen Hospital** · enrollment: 10 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Anidulafungin

## Key facts

- **NCT ID:** NCT01053884
- **Lead sponsor:** Elisabethinen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** reduced recruitment rate due to non infectious, but competitive trials at our institution
- **Last updated:** 2012-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053884, "Anidulafungin in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01053884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*